Drugs / DCB-BO1202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02289300 | Jan 2020 → Jan 2021 | chronic hepatitis B virus infection, fibrotic liver disease, hepatocellular carcinoma | A2 Healthcare Taiwan Corporation | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCB-BO1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289300 ↗ |
| Route | Oral | “t.i.d., orally.” NCT02289300 ↗ |